Laboratorios Farmacéuticos Rovi SA is a Spanish biotechnology and pharmaceutical company specializing in the research, development, manufacturing, and marketing of small molecule and specialty biologi... Laboratorios Farmacéuticos Rovi SA is a Spanish biotechnology and pharmaceutical company specializing in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. Founded in 1946, it operates through two primary segments: Manufacturing, focused on contract development and manufacturing organization (CDMO) services with high-capacity facilities for pre-filled syringes and oral solids, and Marketing, which promotes a diversified portfolio of innovative patented products in Spain via specialized sales to physicians, hospitals, and pharmacies. A cornerstone of its offerings is low molecular weight heparin (HBPM), its flagship product distributed in over 60 countries through strategic international partnerships. The company emphasizes expanding heparin applications for chronic treatments and has recently expanded globally by acquiring an injectable manufacturing site in Phoenix, Arizona, enhancing its U.S. presence and rebranding its CDMO as ROIS. As a member of the IBEX 35 index, Laboratorios Farmacéuticos Rovi SA plays a significant role in the healthcare sector, particularly in drug manufacturing for specialty and generic pharmaceuticals, with 2,188 employees supporting its operations.
Laboratorios Farmaceuticos ROVI's EU Taxonomy Data Preview
In 2024, Laboratorios Farmaceuticos ROVI was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.
The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.
Laboratorios Farmaceuticos ROVI has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Laboratorios Farmaceuticos ROVI are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible A Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Non-Eligible B Turnover
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible A Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Non-Eligible B Opex
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
7.3 CCM/CCA - Installation, maintenance and repair of energy efficiency equipment
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
7.4 CCM/CCA - Installation, maintenance and repair of charging stations for electric vehicles in buildings (and parking spaces attached to buildings)
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
7.5 CCM/CCA - Installation, maintenance and repair of instruments and devices for measuring, regulation and controlling energy performance of buildings
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
7.6 CCM/CCA - Installation, maintenance and repair of renewable energy technologies
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible A Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Non-Eligible B Capex
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
7.3 CCM/CCA - Installation, maintenance and repair of energy efficiency equipment
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
7.4 CCM/CCA - Installation, maintenance and repair of charging stations for electric vehicles in buildings (and parking spaces attached to buildings)
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
7.5 CCM/CCA - Installation, maintenance and repair of instruments and devices for measuring, regulation and controlling energy performance of buildings
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
7.6 CCM/CCA - Installation, maintenance and repair of renewable energy technologies
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Limited Data Preview
You are viewing a limited preview of Laboratorios Farmaceuticos ROVI’s EU Taxonomy dataset. The full dataset, available for download, includes eligibility and alignment metrics for turnover, CAPEX, and OPEX across all EU Taxonomy categories (A1, A2, A, B, and A+B), at both aggregate and activity level, with historical coverage back to 2022.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Used by 1,000+ teams in finance, climate, and research
Verified Sources Behind Laboratorios Farmaceuticos ROVI’s EU Taxonomy Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Laboratorios Farmaceuticos ROVI’s data sources below and access millions more through our Disclosure Search.
a. Laboratorios Farmaceuticos ROVI's Sustainability Report 2024
b. Laboratorios Farmaceuticos ROVI's Integrated Report 2023
c. Laboratorios Farmaceuticos ROVI's Integrated Report 2022
Insights into Laboratorios Farmaceuticos ROVI's Revenues from Sustainable Activities
In 2024, Laboratorios Farmaceuticos ROVI reported EU Taxonomy-eligible revenues of EUR 286.67 million, representing 37.54% of its total turnover. Of this amount, EUR 0 of Laboratorios Farmaceuticos ROVI's revenues was classified as EU Taxonomy-aligned, indicating that 0% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Insights into Laboratorios Farmaceuticos ROVI's CAPEX from Sustainable Activities
In 2024, Laboratorios Farmaceuticos ROVI reported EU Taxonomy-eligible CAPEX of EUR 47.20 million,representing 71.99% of its total CAPEX. Of this amount, EUR 832,357 of Laboratorios Farmaceuticos ROVI's CAPEX was classified as EU Taxonomy-aligned, indicating that 1.27% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Laboratorios Farmaceuticos ROVI's Taxonomy-Eligible Capex Over Time
Total Taxonomy Aligned A1 Capex
Total Taxonomy Eligible but Not Aligned A2 Capex
Have Laboratorios Farmaceuticos ROVI's increased its investment in sustainable activities over time?
Since 2022, Laboratorios Farmaceuticos ROVI's taxonomy-aligned capital expenditure (CAPEX)increased by 48.07%,pointing to a long-term shift toward greater investment in environmentally sustainable activities recognized under the EU Taxonomy.a, c
Compared to the previous year (2023), Laboratorios Farmaceuticos ROVI's taxonomy-aligned CAPEX decreased by 40.84%,suggesting that Laboratorios Farmaceuticos ROVI may have scaled back investments in sustainable projects, reprioritized its capital deployment, or reduced transparency in its taxonomy-aligned disclosures.a, b
How much of Laboratorios Farmaceuticos ROVI's capital expenditure (CAPEX) is eligible under the EU Taxonomy?
In 2024, Laboratorios Farmaceuticos ROVI reported that EUR 47.20 million of its capital expenditure (CAPEX) was eligible under the EU Taxonomy, representing 71.99% of the company's total CAPEX. Of this amount, EUR 832,357 (1.27% of total CAPEX) was classified as Taxonomy-aligned. This means that 70.72% of Laboratorios Farmaceuticos ROVI's CAPEX is eligible but not aligned, indicating that these investments either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).a
How much of Laboratorios Farmaceuticos ROVI's eligible CAPEX is aligned with the EU Taxonomy?
In 2024, Laboratorios Farmaceuticos ROVI reported that EUR 832,357 of its CAPEX was aligned under the EU Taxonomy, representing 1.27% of its total capital investment.a
This low alignment reflects that Laboratorios Farmaceuticos ROVI is beginning to transition its capital allocation toward greener investments, but still retains substantial opportunities for further alignment with sustainability goals.
Laboratorios Farmaceuticos ROVI's Contribution to Environmental Objectives
Total Taxonomy Aligned A1 Capex
Total Taxonomy Eligible but Not Aligned A2 Capex
How is Laboratorios Farmaceuticos ROVI's taxonomy-aligned CAPEX distributed across the EU environmental objectives?
In 2024, Laboratorios Farmaceuticos ROVI reported that its taxonomy-aligned capital expenditure (CAPEX) was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 1.27%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much Laboratorios Farmaceuticos ROVI is investing in climate-related solutions?
In 2024, Laboratorios Farmaceuticos ROVI allocated EUR 832,083 of its CAPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 1.27% of the company's total capital expenditure,indicating that Laboratorios Farmaceuticos ROVIhas only marginally directed its capital expenditure toward climate-related activities, suggesting limited alignment with climate objectives.a
Insights into Laboratorios Farmaceuticos ROVI's OPEX from Sustainable Activities
In 2024, Laboratorios Farmaceuticos ROVI reported EU Taxonomy-eligible OPEX of EUR 9.93 million,representing 26.67% of its total operating expenses (OPEX). Of this amount, EUR 146,883 of Laboratorios Farmaceuticos ROVI's OPEX was classified as EU Taxonomy-aligned, indicating that 0.39% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Laboratorios Farmaceuticos ROVI's Taxonomy-Eligible Opex Over Time
Total Taxonomy Aligned A1 Opex
Total Taxonomy Eligible but Not Aligned A2 Opex
Have Laboratorios Farmaceuticos ROVI's increased its spending in sustainable activities over time?
Since 2022, Laboratorios Farmaceuticos ROVI's taxonomy-aligned operating expenditure (OPEX)increased by 629.63%,pointing to a long-term trend of increased spending on environmentally sustainable operations and services recognized under the EU Taxonomy.a, c
Compared to the previous year (2023), Laboratorios Farmaceuticos ROVI's taxonomy-aligned OPEX increased by 189.71%,highlighting Laboratorios Farmaceuticos ROVI's growing commitment to funding sustainable operations or improving how such expenses are classified and reported under the EU Taxonomy.a, b
How much of Laboratorios Farmaceuticos ROVI's operational expenditure (OPEX) is eligible under the EU Taxonomy?
In 2024, Laboratorios Farmaceuticos ROVI reported that EUR 9.93 million of its operational expenditure (OPEX) was eligible under the EU Taxonomy, representing 26.67% of the company's total OPEX. Of this amount, EUR 146,883 (0.39% of total OPEX) was classified as Taxonomy-aligned. This means that 26.27% of Laboratorios Farmaceuticos ROVI's OPEX is eligible but not aligned, indicating that these expenditures either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).a
How much of Laboratorios Farmaceuticos ROVI's eligible OPEX is aligned with the EU Taxonomy?
In 2024, Laboratorios Farmaceuticos ROVI reported that EUR 146,883 of its OPEX was aligned under the EU Taxonomy, representing 0.39% of its total operational expenditure.a
This low alignment reflects limited operational focus on green activities, suggesting that sustainability considerations have yet to be fully integrated into core operating processes.
Laboratorios Farmaceuticos ROVI's Contribution to Environmental Objectives
Total Taxonomy Aligned A1 Opex
Total Taxonomy Eligible but Not Aligned A2 Opex
How is Laboratorios Farmaceuticos ROVI's taxonomy-aligned OPEX distributed across the EU environmental objectives?
In 2024, Laboratorios Farmaceuticos ROVI reported that its taxonomy-aligned operational expenditure (OPEX) was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 0.39%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much of Laboratorios Farmaceuticos ROVI's operational budget supports climate-related solutions?
In 2024, Laboratorios Farmaceuticos ROVI allocated EUR 146,757 of its OPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 0.39% of the company's total OPEX,indicating that Laboratorios Farmaceuticos ROVIhas only a limited share of operational expenditure aligned with climate goals, signaling early-stage or minimal integration of climate objectives into its routine activities.a
Want Full Access to Laboratorios Farmaceuticos ROVI's EU Taxonomy Dataset?
b
b
a
b
c
b
c
b
c
a
b
c
a
b
c
a
b
c
b
c
b
a
b
c
a
b
c
b
c
a
b
c